Gene therapy takes aim at Hard-to-Treat HER2 cancers
NCT ID NCT07192432
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 4 times
Summary
This study tests a new gene therapy called VNX-202 for people with HER2-positive solid tumors. The therapy uses a harmless virus to deliver instructions that help the body's immune cells attack cancer. The trial has two parts: one for advanced cancers that have stopped responding to standard treatments, and another for early-stage cancers at high risk of coming back. Researchers will monitor safety and whether the treatment controls tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VNX-202 gene therapy (a virus that delivers instructions to make cancer-fighting immune proteins)
- What this could lead to
- If it works, this could offer a new treatment option for people with HER2-positive cancers that have stopped responding to other therapies.
- What could go wrong
- This is a very early, first-in-human study with only 27 participants. The therapy may not shrink tumors or could cause serious side effects. Success in early-stage disease is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 EXPRESSING SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Email: •••••@•••••
-
Hackensack Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Email: •••••@•••••
-
Mayo Clinic
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55095, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
SCRI Denver DDU at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
VCU Massey CTO Phase I Solid Team
RECRUITINGRichmond, Virginia, 23298, United States
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.